ABC | Volume 110, Nº2, February 2018

Original Article Gripp et al Global Longitudinal Strain Accuracy for Cardiotoxicity Arq Bras Cardiol. 2018; 110(2):140-150 1. Center forDiseaseControlandPrevention (CDC).Cancersurvivors—United States, 2007. MMWR. 2011;60(9):269-72. PMID: 21389929. 2. Schimmel KJ, Richel DJ, Van Den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev . 2004;30(2):181-91. doi: 10.1016/j. ctrv.2003.07.003. 3. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231-47. doi: 10.1016/j.jacc.2009.02.050. 4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al; Authors/Task ForceMembers; ESCCommittee for Practice Guidelines (CPG). 2016. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESCCommittee for Practice Guidelines. Eur Heart J. 2016;37(36):2768-801. doi: 10.1093/ eurheartj/ehw211. 5. Seidman A, Hudis C, Pierri MC, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-1221. doi: 10.1200/JCO.2002.20.5.1215. 6. Florescu M, Magda LS, Enescu OA, Jinga D, Vinereanu D. Early detection of doxorubicin- induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr. 2014;27(1):83-92. doi: 10.1016/j.echo.2013.10.008. 7. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;128(16):e240-327. doi: 10.1161/ CIR.0b013e31829e8776 8. Martin M, Esteva FJ, Alba E, Khandheria B, Pérez-Isla L, García-Sáenz JA. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations. Oncologist. 2009;14(1):1-11. doi: 10.1634/theoncologist.2008-0137. 9. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62(6):865-72. PMID: 667860. 10. Force T. Introduction to cardiotoxicity review series. Circ Res. 2010;106(1):19-20. doi: 10.1161/CIRCRESAHA.109.210724. 11. Tan T, Bouras S, Sawaya H, Sebag IA, Cohen V, PicardMH, et al. Time trends of left ventricular ejection fraction and myocardial deformation indices in a cohort of women with breast cancer treated with anthracyclines, taxanes, and trastuzumab. J AmSoc Echocardiogr. 2015;28(5):509-14. doi: 10.1016/j.echo.2015.02.001. 12. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert Consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of EchocardiographyandtheEuropeanAssociationofCardiovascular Imaging. J AmSocEchocardiogr.2014;27(9):911-39.doi:10.1016/j.echo.2014.07.012. 13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J AmSoc Echocardiogr 2015;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003. 14. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493-8. doi: 10.1016/j.echo.2013.02.008. 15. Thavendiranathan P, Poulin F, LimKD, Plana JC, Woo A, Amarwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy– A Systematic Review. J Am Coll Cardiol. 2014;63(25 Pt A):2751-68. doi: 10.1016/j.jacc.2014.01.073. 16. Sawaya H, Sebag I, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375-80. doi: 10.1016/j.amjcard.2011.01.006. 17. Baratta S, Damiano MA, Marchese ML, Trucco JI, Rizzo M, Bernok F, et al. Serum markers, conventional Doppler echocardiography and two- dimensional systolic strain in the diagnosis of chemotherapy-Induced myocardial toxicity. Rev Argent Cardiol. 2013;81:139-46. doi: http://dx.doi . org/10.7775.rac.v81.i2.2497. 18. Matos E, Jug B, Blagus R, Zakotnik B. A prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients. Arq Bras Cardiol. 2016;107(1):40-7. doi: 10.5935/abc.20160084. 19. Tan TC, Bouras S, Sawaya H, Sebag IA, Cohen V, Picard MH, et al. Time trends of left ventricular ejection fraction and myocardial deformation indices in a cohort of womenwith breast cancer treatedwith anthracyclines, taxanes, and trastuzumab. J AmSoc Echocardiogr. 2015;28(5):509-14. doi: 10.1016/j.echo.2015.02.001. 20. Charbonnel C, Convers-Domart R, Rigaudeau S, Taksin AL, Baron N, Lambert J, et al. Assessment of global longitudinal strain at low- dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity. Eur Heart J Cardiovasc Imaging. 2017;18(4):392-401. doi: 10.1093/ehjci/jew223. 21. Almeida AL, Silva VA, de Souza Filho AT, Rios VG, Lopes JR, de Afonseca SO, et al. Subclinical ventricular dysfunction detected by speckle tracking two years after use of anthracycline. Arq Bras Cardiol. 2015;104(4):274-83. doi: 10.5935/abc.20140209. 22. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes. J Am Coll Cardiol. 2013;61(1):77-84. doi: 10.1016/j.jacc.2012.09.035. 23. Van SmedenM, DeGroot JA, Moons KG, Collins GS, AltmanDG, Eijkemans MJ, et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis. BMC Med Res Methodol. 2016;16(1):163. doi: 10.1186/s12874-016-0267-3. 24. Courvoisier DS, Combescure C, Agoritsas T, Gayet-Ageron A, Perneger TV. Performance of logistic regression modeling: beyond the number of events per variable, the role of data structure. J Clin Epidemiol. 2011;64(9):993- 1000. doi: 10.1016/j.jclinepi.2010.11.012. References 149